Notably, the critical role of mutations in epigenetic regulators and splicing factors, such as ASXL1 [53,54], SRSF2 [55] and U2AF1 [56], in impaired hematopoiesis and the development of myelodysplastic syndromes (MDS), was validated in preclinical and clinical [57] studies. This evidence concerns the gene ASXL1 and myelodysplastic syndrome.